Inactivated and subunit vaccines to prevent shigellosis

Abstract

Shigellosis remains a formidable disease globally, with children of the developing world bearing the greatest number of infections. The need for an affordable, safe and efficacious vaccine has persisted for decades. Vaccines to prevent shigellosis can be divided into living and nonliving approaches. Several nonliving Shigella vaccines are currently at different stages of development and show substantial promise. Outlined here is an overview of multiple nonliving vaccine technologies, highlighting their current status and recent advances in testing. In addition, gaps in the knowledge base regarding immune mechanisms of protection are explored.

Keywords::

• lipopolysaccharide
• Ipa
• LPS
• Shigella
• subunit vaccines

Acknowledgements

The authors are grateful to K Ross Turbyfill, R Ranallo and R Bowden for critical review of the manuscript.

Financial & competing interests disclosure

The content of this publication does not necessarily reflect the views or policies of the US Department of the Army or the US Department of Defense, nor does the mention of trade names, commercial products, or organizations imply endorsement by the US government. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.